Davidson Ebru 4

What Happened

• Davidson Ebru, a director of Kazia Therapeutics (KZIA), received a board-approved award of 100,000 options over American Depositary Shares (ADSs) on January 8, 2026. The options were granted for no cash consideration and are derivative securities (not immediate share purchases).
• Each option carries an exercise price of $9.10 per ADS. The options vest on January 8, 2027 and expire on January 8, 2029. Because this is a grant (award), it is not an immediate buy or sale of stock.

Key Details

• Transaction date: January 8, 2026 (reported filing date: July 8, 2026 — filing appears late).
• Grant: 100,000 options; exercise price $9.10 per ADS.
• Vesting: January 8, 2027. Expiration: January 8, 2029.
• Consideration: granted for no consideration (no cash paid at grant).
• Shares owned after transaction: not specified in the filing.
• Footnote: exercise price reflects Australian tax considerations for Australian-resident participants and the award was approved by the Remuneration Committee on Jan 8, 2026.
• Timeliness: The Form 4 was filed about six months after the grant date; this is later than the usual Form 4 reporting window and reduces near-term transparency.

Context

• These are stock options (a derivative grant). If and when Ebru vests and exercises them, he would pay $9.10 per ADS to acquire the underlying shares; the filing does not indicate any exercise or sale occurred.
• Grants are common for board members as compensation; they do not necessarily signal an immediate trading view. Late reporting can matter to investors because it delays public visibility into insider compensation and holdings.